Glaukos (GKOS) received a Hold rating from Wells Fargo analyst Larry Biegelsen today. The company’s shares closed last Monday at $66.06, close to its 52-week high of $70.96.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 19.0% and a 69.5% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Merit Medical Systems.
Currently, the analyst consensus on Glaukos is a Hold with an average price target of $56.25, implying a -16.8% downside from current levels. In a report issued on November 2, BTIG also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Based on Glaukos’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $64.83 million and GAAP net loss of $15.75 million. In comparison, last year the company earned revenue of $58.51 million and had a GAAP net loss of $13.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
